INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

	Application Number		10807165		
	Filing Date		2004-03-24		
	First Named Inventor	Chla	dny		
Art Unit			3611		
	Examiner Name	Cass	andra Hope Davis		
	Attornous Dookset Mumb		Learne		

	U.S.PATENTS								
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Linas where Relevant Passeges or Relevan Figures Appear			
	1	5657566		1997-08-19	Key				
	2	6109639		2000-08-29	Blassingame et al.				
	3	6122850		2000-09-26	Strzeletz				
	4	6904709		2005-06-14	Craig et al.				

ion information please click the Add button.

### U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20030094315		2003-05-22	White	
	2	20040262671		2004-12-30	Schreuder et al.	

If you wish to add additional U.S. Published Application citation Information please click the Add button.

FOREIGN PATENT DOCUMENTS

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

oplication Number		10807165		
ing Date		2004-03-24		
rst Named Inventor	Chlad	dny		
t Unit		3611		
xaminer Name Cass		andra Hope Davis		
tomou Dookst Number		12020 0		

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> j	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T5	
	1							_	
If you wish to edd additional Foreign Patent Document citation information please click the Add button									
NON-PATENT LITERATURE DOCUMENTS									
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city endlor country where published.							Ţ6	
	,								

EXAMINER SIGNATURE

Ā

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformence with MPEP 609. Drew line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at your USPTO GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the potent document. \* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible \* Applicant is to place a check merk here it English language translation is attached.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

oplication Number		10807165	-	
Ing Date rst Named Inventor Chia		2004-03-24		
		dny		
t Unit		3611		
xaminer Nama	Cass	landra Hope Davis		
tomey Docket Numb	er	13526-6		

### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s);

	That each item of information contained in the information disclosure statement was first cited in any communication
	from a foreign patent office in a countarpart foreign application not more than three months prior to the filing of the
	information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no term of information contained in the information disclosure statement was cited in a communication from a foreign patient office in a counterpart foreign epistents, and, to be invokating of the person signing the certification after making reasonable inquiry, no tien of information contained in the information disclosure statement was known to any individual designated in 37 CPR 1.56(c) more than three morthing from the filling of the information disclosure.

See attached certification statement

- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
  - □ None

### SIGNATURE

A signature of the applicant or representative is required in accordence with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signeture.

Signature	/jar/	Dete (YYYY-MM-DD) 2006-12-20			
Name/Print	James A. Raakman	Registration Number	56,624		

This collection of information is required by 37 CFR 197 and 1.98. The Information is required to obtain or retain a benefit by the public which is to like (and by the ISPOTO to process) are agricultaneously collection of the CFR 1.97 and 1.98. The CFR 1.14. This collection is estimated to take 1 hour to complete, including againstring, propering and submitting the completed application from the Intellection of the ISPOT. Time will vary depending upon the Intellection 250 and 250 and 250 and 250 are required to complete this form and/or suggestions for making his burden, should be sent to the Chief information Officer, U.S. Pattern and Trademick Office, U.S. Designation of Commence, O.P. Gen 1493, Austractic v. V. 2231-3450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1459, Abstanding, V.2231-3450.

#### Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the actual catached form resident to a patient application or patient. Accordingly, pursuant to the requirements of the Act please be advised that: (1) the general authority for the collection of this information is 30 U.S.C. 2(b)(2); (2) furnishing of the information solicided is voluntary, and (3) for privipal purpose of vehich the information is used by the U.S. Patient and Trademies Cffice is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested or patient and the privilence of the patient application or patient. If you do not furnish the requested of the patient application or patient. If you do not furnish the requested of the patient patient patient and the patient patient and the patient patient patient and the patient patient patient patient patients.

The information provided by you in this form will be subject to the following routine uses:

- The Information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system or feconds may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as e routine use, in the course of presenting evidence to a
  court, magistrate, or edministrative tribunal, including disclosures to opposing counsal in the course of satitament
  negotiation.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting e request involving an individuel, to whom the record pertains, when the individual hes requested assistance from the Member with respect to the subject mailer of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 582e(m).
- A record railated to an International Application filed under the Petent Cooperation Treaty in this system of records
  mey be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
  to the Petent Cooperation Treaty.
- A racord in this system of records may be disclosed, es a routine use, to another federel egency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Sprices, or hishor designers, outing an inspection of records conducted by QSAs ape and frost dealergive repossibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 294 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing improcion of records for this purpose, and any other invitabilities and programs of the contraction of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application prayment to \$50 U.S.C. 125 (routine) or partner prasment of \$50 U.S.C. 125 (routine) are confirmed to disclosed, subject to the limitations of \$10 CFR 114, as a routine use, to the public the forecord was find in an application published application, on application open to published applications or an application of the published application, on application open to publish respections or an instead patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.